IL6 and infection: However, considering the mechanism of action of siltuximab, which binds to IL-6 as an anti-IL-6 chimeric monoclonal antibody and interferes with IL-6 mediated growth of B-lymphocytes, plasma cells, and secreting vascular endothelial growth factor, siltuximab may lower a patient’s resistance to infections (28).